ClinicalTrials.gg
RecruitingNCT05426252Updated Dec 19, 2023

Thal-Fabs: Reduced Toxicity Conditioning for High Risk Thalassemia

A Phase 1/2 interventional study of Abatacept and Sirolimus in Thalassemia in Children, sponsored by The Hospital for Sick Children. Recruiting at 1 site in Canada. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2023-12-19.

Sponsored by The Hospital for Sick Children · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Mar 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
1 Year to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies in Thalassemia with a site in Canada — 4 open to participants now, 9 under way, 5 of them phase 3. Thalassemia · Canada.

Planned enrollment
13th of 17
20 · median 55
Started
2022
with 2 others
Phase 1/2
Only one
of the 22
Registered
20th of 22
by date
Lead sponsor
1 of 22
The Hospital for Sick Children

Among the 22 studies in Thalassemia with a site in Canada, this one is the 13th largest by planned enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2022, is the only one in phase 1/2, and was the 20th registered.

Thalassemia

252 studies on the registry are indexed under Thalassemia; 45 are open to participants now.

Browse Thalassemia studies →

Open to participants now

4 of the 22 studies in Thalassemia with a site in Canada are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 29 Thalassemia studies recruiting now, 8 (28%) set no upper age limit and 18 (62%) stop at 75 or younger; 22 take children under 18; none take healthy volunteers.

This study: 1 Year to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Thalassemia with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate a novel transplant strategy for the long-term benefit of patients with transfusion dependent high-risk thalassemia.

Read the detailed description

Patients with high-risk thalassemia meeting the eligibility criteria for this study will be entered sequentially until completion or closure of the study.

The hypothesis is that a reduced-toxicity conditioning regimen combined with pre-transplant immunosuppression, followed by abatacept and sirolimus as graft-versus-host disease (GVHD) prophylaxis for allogeneic transplant with either Human Leukocyte Antigen (HLA)-matched sibling donors or haploidentical donors is feasible and safe and can be delivered with less toxicity, durable donor engraftment, and minimal GVHD.

03

Conditions studied

  • Thalassemia in Children

Browse trials for

Keywords

  • thalassemia
  • reduced toxicity
  • abatacept
  • sirolimus
  • pre transplant immunosuppression
04

Who can participate

Ages eligible
1 Year to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: In order to be eligible to participate in this study, the recipient must meet all of the following criteria:

  1. Patients with a diagnosis of transfusion dependent beta or alpha thalassemia (3 or 4 gene deletion) between the age of 1-18 years.
  2. Thalassemia genotype must be confirmed by molecular genetic testing.
  3. Patients with thalassemia must have at least one of the high-risk features:

    • Age >7 years
    • Hepatomegaly (2 cm below costal margin)
    • Inadequate iron chelation (liver iron content >7mg/g dry weight)
    • Severe alloimmunization
    • Unable to tolerate iron chelation
  1. Patients must have had a complete evaluation of their iron status including measurement of serum ferritin, MRI of the heart and liver (within the previous 6 months prior to referral). Liver elastography (within the preceding 3 months) will be also obtained but not required.
  1. Ability to take oral medication and be willing to adhere to the study regimen.
  1. Patients who have a performance status of at least 70% or Lansky status prior to transplantation.
  1. Patients who are acceptable candidates for marrow transplantation based on their pre-BMT evaluation.
  1. Patients who have histocompatibility sibling or HLA haplo identical family member and have been medically approved as hematopoietic progenitor cell donors.
  1. Patients who are not candidates for gene therapy.
  1. Patients/legal guardians who sign for the protocol approved by the Research Ethical Board of the Hospital for Sick Children/University of Toronto.

Exclusion Criteria: The recipient who meets any of the following criteria will be excluded from participation in this study:

  1. Patients will not be excluded based on sex, race, or ethnic background.
  2. Patients will be excluded if they demonstrate significant functional deficits in major organs, which could interfere with the outcome following bone marrow transplant, including:

    • Cardiac: Evidence of significant cardiac dysfunction (resting of \< 50% with absence of improvement with exercise), marked cardiomegaly or uncontrollable hypertension.
    • Renal: Evidence of > 50% reduction in expected or \< 60mL/min/1.73m2
    • Hepatic: Evidence of hepatic dysfunction evidenced by a serum direct (conjugate) of > 2.5 mg/dl, or > 5 times the for age.
    • Pulmonary: Evidence of focal or diffuse active infection or pneumonitis and the patient demonstrates a \< 50% or carbon monoxide diffusing capacity (DLCO) of \< 50% predicted value (adjusted for ). The patient should not require ventilation support.
  3. Presence of donor specific antibody (DSA) with mean fluorescence intensity (MFI) greater than 3,000.
  4. Previous stem cell transplant or gene therapy.
  5. Presence of cardiomyopathy with a T2* \< 10ms per Cardiac MRI.
  6. Presence of significant liver iron deposition defined as liver iron content >15mg/g liver dry weight. If iron chelation were optimized and reassessment within 6 months shows a decrease of LIC to \<15 with no evidence of cardiomyopathy, patient may still be considered for enrollment.
  7. Active , or disease.
  8. Severe liver cirrhosis or bridging fibrosis on liver if previously done.
  9. Prior or current or myeloproliferative or immunodeficiency disorder.
  10. Evidence of active, deep seated, life-threatening infections despite therapy (e.g., certain fungal species, HIV, etc.).
  11. Patients will be excluded if they are women of who are currently pregnant (b-HCG+) or who are not practicing adequate .
  12. Any condition that would preclude serial follow up.
  13. Patients with a known life-threatening allergy to components of the pre transplant (fludarabine), conditioning (treosulfan, cyclophosphamide or anti-thymocyte globulin) or graft versus host prophylactic regimen (abatacept, sirolimus).
  14. Any condition or diagnosis, that could in the opinion of the Principal Investigator or delegate interfere with the participant's ability to comply with study instructions, might confound the interpretation of the study results, or put the participant at risk

Donor Eligibility:

Donors will not be considered research subjects as the stem cell collection procedure is standard of care and will not be considered part of the research.

In order to be eligible to participate in this study, the donor must meet all of the following criteria:

  1. May have thalassemia or sickle trait.
  2. Will also consider ABO match and lack of donor specific anti-HLA antibodies.
  3. Donors must be minimal of 15 kg weight and have completed routine donor evaluations as per our standard of care.
  4. Donors must have signed (by patient or legal guardian) informed consent for the protocol approved by the Research Ethical Board of the Hospital for Sick Children/University of Toronto.
  5. No evidence of transmissible diseases in compliance with the Health Canada CTO regulations
  6. Not pregnant or lactating
  7. Must not be allergic to granulocyte colony stimulating factor (G-CSF)
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    PTIS followed by abatacept and sirolimus

    Administration of reduced-toxicity conditioning regimen combined with pre-transplant immunosuppression, followed by abatacept and sirolimus as graft-versus-host disease (GVHD) prophylaxis for allogeneic transplant with either Human Leukocyte Antigen (HLA)-matched sibling donors or haploidentical donors

    Drug: Abatacept · Drug: Sirolimus

Interventions

  • Abatacept, co-stimulation blockade, to be given for GVHD prophylaxis in combination with sirolimus post allogeneic hematopoietic stem cell transplantation.

    Also known as: Orencia

  • Sirolimus, mTOR inhibitor, to be given for GVHD prophylaxis in combination with abatacept post allogeneic hematopoietic stem cell transplantation.

    Also known as: Rapamicin

06

What researchers measure

Primary outcomes

  1. Number of patients who have WBC engraftment by day +100

    Rate of neutrophil engraftment defined by the first day of 3 consecutive days of absolute neutrophil counts above 500/uL after bone marrow transplant.

    Time frame: Until Day +100

  2. Number of patients who develop Grade II to IV acute GVHD at Day +100

    Incidence of Grade II or greater acute graft-versus-host disease (GvHD) post-transplant using criteria by Przepiorka et al, 1994

    Time frame: Until Day +100

  3. Immune reconstitution

    Rate of immune reconstitution defined by recovery of CD4 cells post bone marrow transplantation

    Time frame: Until Day +365

Secondary outcomes

  1. Number of patients who develop Chronic GVHD

    Incidence of chronic GVHD using NIH consensus staging system at 6 months and 1 year

    Time frame: Day +100 until Day +365

Other outcomes

  1. Number of patients who will wean Sirolimus at 1 year post transplant

    Numbers of patients eligible to wean sirolimus at 1 year.

    Time frame: Until Day +365

  2. Length of stay

    Numbers of length of hospital stay after bone marrow transplant

    Time frame: Until Day +365

  3. Cost effectiveness

    Amount of cost including utilization of healthcare throughout transplant

    Time frame: Until Day +365

07

Study locations

1 of 1 sites recruiting
  • Yogi Chopra
    Toronto, Ontario, Canada
    Recruiting
    • Yogi Chopra · Contactyogi.chopra@sickkids.ca
    • Erilda Kapllani · Contactbmt.cra@sickkids.ca
    • Donna Wall, MD · Sub investigator
    • Muhammed Ali, MD · Sub investigator
    • Joerg Krueger, MD · Sub investigator
    • Tal Schechter, MD · Sub investigator
    • Melanie Kirby, MD · Sub investigator
    • Isaac Odame, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2022 (actual). Primary completion is estimated for Dec 2025, 45 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2022
First posted
Jun 21, 2022
StartActual
Mar 22, 2022
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2026
Last update
Dec 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05426252
Collaborators
Thalassemia Foundation of Canada
Responsible party
Yogi Chopra (Staff Physician, The Hospital for Sick Children) — Principal investigator
First posted
Jun 21, 2022
Start date
Mar 22, 2022
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Dec 19, 2023

Study contacts

Yogi Chopra, MD
Contact
yogi.chopra@sickkids.ca
+1 (416) 813-7654 ext. 201103
Erilda Kapllani
Contact
bmt.cra@sickkids.ca
+1 (416) 813-7654 ext. 202831
Yogi Chopra, MD
principal investigator · The Hospital for Sick Children

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abatacept · Sirolimus

Start the discussion